Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-001847-16 | EudraCT Number | ||
| 2023-507418-28-00 | EU Trial (CTIS) Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC) | Experimental | Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) ≥ 1.51 square meter (m^2). The total dose of daily entrectinib administration for pediatric participants with BSA < 1.51 m^2 will be lower. |
|
| Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors | Experimental | Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m^2. The total dose of daily entrectinib administration for pediatric participants with BSA < 1.51 m^2 will be lower. |
|
| Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC) | Experimental | Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles. |
|
| Cohort D: TMB-high Tumors | Experimental | Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Entrectinib | Drug | Adults and pediatric participants with a BSA ≥1.51 m^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m^2) or 300 mg/day (BSA=0.81-1.10 m^2) or 200 mg/day (BSA=0.51-0.80 m^2) or 300 milligrams per square meter (mg/m^2) (BSA=0.43-0.50 m^2). |
| Measure | Description | Time Frame |
|---|---|---|
| All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | Confirmed objective response indicates ≥4 weeks after initial documentation of response. | Approximately up to 12 years |
| Measure | Description | Time Frame |
|---|---|---|
| All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1 | Approximately up to 12 years | |
| All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1 | Approximately up to 12 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Western Regional Medical Center at Cancer Treatment Centers of America | Goodyear | Arizona | 85338 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41213248 | Derived | Bagchi A, Chiang J, Pinto S, Dhanda S, Gajjar A. Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features. J Natl Compr Canc Netw. 2025 Nov;23(11):e257064. doi: 10.6004/jnccn.2025.7064. | |
| 40086048 | Derived | Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22. |
Not provided
Not provided
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors | Experimental | Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants < 35 kilograms (kg), 300 mg for participants ≥ 35 and < 45 kg, 400 mg for those ≥ 45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed. |
|
| Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors | Experimental | Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days. Note: Cohort F has been closed as of protocol version 7 because enrollment and participant follow-up have been completed. |
|
| Cohort H: PIK3CA Multiple Mutant-positive Tumors | Experimental | Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles. Note: Cohort H has been closed for enrollment. |
|
| Cohort I: BRAF Class II Mutant or Fusion-positive Tumors | Experimental | Participants with proto-oncogene B-Raf (BRAF) class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib, PO, BID with adequate water (more than 200 milliliters [mL]). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed. |
|
| Cohort J: BRAF Class III Mutant-positive Tumors | Experimental | Participants with BRAF class III mutant-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib PO BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort J has been closed for enrollment. |
|
| Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC) | Experimental | Participants with RET fusion-positive tumors will self-administer pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days). Note: Cohort K has been closed. |
|
| Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC]) | Experimental | Participants with kirsten rat sarcoma virus (KRAS) G12C-positive tumors will self-administer divarasib (GDC-6036) orally at home (except on clinic days). |
|
| Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors | Experimental | Participants with ATM LOF tumors will self-administer camonsertib orally at home (except on clinic days). Note: Cohort M has been closed. |
|
| Cohort N: SETD2 LOF Tumors | Experimental | Participants with methyltransferase SET (Su(var) 3-9) Enhancer of zest and Trithorax) domain-containing 2 (SETD2) LOF tumors will self-administer camonsertib orally at home (except on clinic days). Note: Cohort N has been closed. |
|
|
|
| Entrectinib | Drug | Adults and pediatric participants with a BSA ≥ 1.51 m^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m^2) or 300 mg/day (BSA=0.81-1.10 m^2) or 200 mg/day (BSA=0.51-0.80 m^2) or 300 mg/m^2 (BSA=≤0.50 m^2). |
|
|
| Alectinib | Drug | Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules). |
|
|
| Atezolizumab | Drug | Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged <18 years on Day 1 of each 21-day cycle. |
|
|
| Ipatasertib | Drug | For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants < 35 kg, 300 mg for participants ≥35 and < 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent. |
|
| Trastuzumab emtansine | Drug | Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age. |
|
|
| Inavolisib | Drug | GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age. |
|
|
| Belvarafenib | Drug | Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. |
|
| Pralsetinib | Drug | Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days). |
|
|
| Divarasib | Drug | Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days). |
|
|
| Camonsertib | Drug | Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle. |
|
| All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: INV-assessed DOR per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: INV-assessed CBR per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: INV-assessed PFS per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1 | Approximately up to 12 years |
| All Cohorts: Overall Survival (OS) | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-oncology (RANO) | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC) | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed DOR per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed CBR per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed PFS per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed ORR per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed DOR per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed CBR per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed PFS per INRC | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed Intracranial (IC)-ORR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS Rate per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS Rate per RECIST v1.1 | Approximately up to 12 years |
| Cohorts A, B and F: Percentage of Participants With Confirmed Deterioration as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
| Cohorts A, B and F: Change From Baseline in the EORTC-QLQ-C30 Total Score | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
| Cohorts A, B and F: Percentage of Participants With a Clinical Meaningful Change on the Global Health Status, Physical Functioning, and Role Functioning Scores From the EORTC QLQ-C30 | The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points. | Approximately up to 12 years |
| Cohorts A, B and F: Time to Confirmed Symptom Onset or Worsening From Tumor-related Symptom Scores From the EORTC QLQ-C30 and EORTC Item Library 71 (IL71) | The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30. | Approximately up to 12 years |
| All Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AE severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.) | Approximately up to 12 years |
| Cohort F: Serum Concentration of Trastuzumab Emtansine at Specified Timepoints | Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (up to approximately 25 months) (one Cycle=21 days) |
| Cohort F: Percentage of Participants with Anti-drug Antibodies (ADA) | Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (up to approximately 25 months) (one Cycle=21 days) |
| Kaiser Permanente Los Angeles |
| Los Angeles |
| California |
| 90027 |
| United States |
| USC Norris Cancer Center | Los Angeles | California | 90033 | United States |
| Hoag Memorial Hospital | Newport Beach | California | 92658 | United States |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | United States |
| University Cancer & Blood Center, LLC | Athens | Georgia | 30607 | United States |
| St. Alphonsus | Boise | Idaho | 83706 | United States |
| Midwestern Regional Med Center | Zion | Illinois | 60099 | United States |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | United States |
| Maryland Hematology & Oncology. P.A. | Silver Spring | Maryland | 20904 | United States |
| Henry Ford Health System | Detroit | Michigan | 48202 | United States |
| Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | United States |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana | Billings | Montana | 59102 | United States |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | United States |
| University of New Mexico | Albuquerque | New Mexico | 87131 | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | 11101 | United States |
| Montefiore Einstein Center for Cancer Care | The Bronx | New York | 10461 | United States |
| Barrett Cancer Center | Cincinnati | Ohio | 45219 | United States |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | United States |
| Consultants in Medical Oncology and Hematology | Broomall | Pennsylvania | 19008 | United States |
| Alliance Cancer Specialists | Horsham | Pennsylvania | 19044 | United States |
| Virginia Cancer Specialists - Leesburg | Leesburg | Pennsylvania | 20176 | United States |
| Cancer Treatment Centers of America | Philadelphia | Pennsylvania | 19124 | United States |
| The West Clinic | Germantown | Tennessee | 38138 | United States |
| St. Jude Children'S Research Hospital | Memphis | Tennessee | 38105 | United States |
| Texas Oncology - Central South | Austin | Texas | 78731 | United States |
| Mary Crowley Medical Research Center | Dallas | Texas | 75230 | United States |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | United States |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | United States |
| Texas Oncology- Northeast Texas | Tyler | Texas | 75702 | United States |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | United States |
| Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |
| Kinghorn Cancer Centre | Darlinghurst | New South Wales | 2010 | Australia |
| Princess Alexandra Hospital | Woolloongabba | Queensland | 4102 | Australia |
| Peter MacCallum Cancer Centre | Melbourne | Victoria | 3000 | Australia |
| Royal Children's Hospital | Parkville | Victoria | 3052 | Australia |
| Cliniques Universitaires St-Luc | Brussels | 1200 | Belgium |
| GHdC Site Les Viviers | Charleroi | 6060 | Belgium |
| UZ Antwerpen | Edegem | 2650 | Belgium |
| UZ Gent | Ghent | 9000 | Belgium |
| UZ Leuven Gasthuisberg | Leuven | 3000 | Belgium |
| Hospital Sírio-Libanês | São Paulo | São Paulo | 01308-050 | Brazil |
| Hospital A. C. Camargo | São Paulo | São Paulo | 01509-010 | Brazil |
| Clínica Onco Star - Rede D'Or | São Paulo | São Paulo | 04543-000 | Brazil |
| BC Cancer ? Vancouver | Vancouver | British Columbia | V5Z 1J3 | Canada |
| The Ottawa Hospital - General Campus | Ottawa | Ontario | K1H 8L6 | Canada |
| The Hospital for Sick Children | Toronto | Ontario | M5G 1H3 | Canada |
| Beijing Cancer Hospital | Beijing | 100142 | China |
| Beijing Children's Hospital, Capital Medical University | Beijing | China |
| West China Hospital - Sichuan University | Chengdu | 610047 | China |
| Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai | 200092 | China |
| Zhongshan Hospital Fudan Unvierstiy | Shanghai | China |
| Tianjin Cancer Hospital | Tianjin | 300060 | China |
| First Affiliated Hospital of Medical College of Xi'an Jiaotong University | Xi'an | 710061 | China |
| Rigshospitalet | København Ø | 2100 | Denmark |
| Institut Bergonie | Bordeaux | 33076 | France |
| Centre Oscar Lambret | Lille | 59020 | France |
| Centre Leon Berard | Lyon | 69373 | France |
| Hopital de la Timone | Marseille | 13005 | France |
| Institut Universitaire du Cancer de Toulouse-Oncopole | Toulouse | 31059 | France |
| Institut de Cancerologie Gustave-Roussy (IGR) | Villejuif | 94805 | France |
| Uniklinik Essen | Essen | 45122 | Germany |
| Georg-August-Uniklinik | Göttingen | 37075 | Germany |
| SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III | Heilbronn | 74078 | Germany |
| Praxis für Hämatologie, Onkologie und Palliativmedizin | Mönchengladbach | 41066 | Germany |
| Hong Kong Children's Hospital | Hong Kong | Hong Kong |
| Prince of Wales Hospital | Shatin | Hong Kong |
| Rambam Health Care Campus | Haifa | 3109601 | Israel |
| Hadassah University Hospital - Ein Kerem | Jerusalem | 9112001 | Israel |
| Rabin MC | Petah Tikva | 4941492 | Israel |
| Sheba Medical Center | Ramat Gan | 5262100 | Israel |
| Sourasky / Ichilov Hospital | Tel Aviv | 6423906 | Israel |
| Ospedale Pediatrico Bambino Gesù - IRCCS | Rome | Lazio | 00165 | Italy |
| Policlinico Universitario Agostino Gemelli IRCCS | Rome | Lazio | 00168 | Italy |
| Asst Degli Spedali Civili Di Brescia | Brescia | Lombardy | 25100 | Italy |
| Irccs Istituto Nazionale Dei Tumori (Int) | Milan | Lombardy | 20133 | Italy |
| Istituto Nazionale Tumori di Milano | Milan | Lombardy | 20133 | Italy |
| Dipartimento di Scienze Pediatriche Adolescenza | Turin | Piedmont | 10126 | Italy |
| Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica | Siena | Tuscany | 53100 | Italy |
| Kindai University Hospital | Osaka | 589-8511 | Japan |
| National Cancer Center Hospital | Tokyo | 104-0045 | Japan |
| Auckland City Hospital, Cancer and Blood Research | Auckland | 1023 | New Zealand |
| Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii | Gda?sk | 80-214 | Poland |
| Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad | Warsaw | 02-781 | Poland |
| IPO do Porto | Porto | 4200-072 | Portugal |
| PanOncology Trials | San Juan | 00935 | Puerto Rico |
| National University Hospital | Singapore | 119228 | Singapore |
| National Cancer Centre | Singapore | 168583 | Singapore |
| Seoul National University Bundang Hospital | Gyeonggi-do | 13620 | South Korea |
| Seoul National University Hospital- Adult Site | Seoul | 03080 | South Korea |
| Seoul National University Hospital- Pediatric Site | Seoul | 03080 | South Korea |
| Severance Hospital, Yonsei University Health System | Seoul | 03722 | South Korea |
| Asan Medical Center | Seoul | 05505 | South Korea |
| Samsung Medical Center- Adult Site | Seoul | 06351 | South Korea |
| Samsung Medical Center- Pediatric Site | Seoul | 06351 | South Korea |
| Hospital Sant Joan De Deu | Esplugues de Llobregas | Barcelona | 08950 | Spain |
| Vall d'Hebron Institute of Oncology (VHIO), Barcelona | Barcelona | 08035 | Spain |
| Vall d?Hebron Institute of Oncology (VHIO), Barcelona | Barcelona | 08035 | Spain |
| Hospital Infantil Universitario Nino Jesus | Madrid | 28009 | Spain |
| Clinica Universidad de Navarra Madrid | Madrid | 28027 | Spain |
| START Madrid-FJD, Hospital Fundacion Jimenez Diaz | Madrid | 28040 | Spain |
| Hospital Universitario 12 de Octubre | Madrid | 28041 | Spain |
| Hospital Universitario La Paz | Madrid | 28046 | Spain |
| START Madrid. Centro Integral Oncologico Clara Campal | Madrid | 28050 | Spain |
| Hospital Universitario la Fe | Valencia | 46026 | Spain |
| Inselspital, Klinik und Poliklinik für Medizinische Onkologie | Bern | 3010 | Switzerland |
| National Cheng Kung University Hospital | Tainan | 00704 | Taiwan |
| Taipei Veterans General Hospital | Taipei | 112201 | Taiwan |
| Chang Gung Memorial Hospital-Linkou | Taoyuan County | 333 | Taiwan |
| National Taiwan University Hospital | Zhongzheng Dist. | 10048 | Taiwan |
| Beatson West of Scotland Cancer Centre | Glasgow | G12 0YN | United Kingdom |
| University College London Hospital | London | NW1 - 2PG | United Kingdom |
| The Christie NHS Foundation Trust | Manchester | M20 4BX | United Kingdom |
| ID | Term |
|---|---|
| C000607349 | entrectinib |
| C582670 | alectinib |
| C000594389 | atezolizumab |
| C583616 | ipatasertib |
| D000080044 | Ado-Trastuzumab Emtansine |
| C000723546 | inavolisib |
| C000655704 | pralsetinib |
| ID | Term |
|---|---|
| D008453 | Maytansine |
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D047029 | Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D000068878 | Trastuzumab |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided